World Health Organization Collaborating Centre for Reference and Research on Influenza, Melbourne, Victoria, Australia.
Monash University, Melbourne, Victoria, Australia.
J Med Virol. 2016 Oct;88(10):1725-32. doi: 10.1002/jmv.24516. Epub 2016 Mar 22.
Current seasonal influenza vaccines require regular updates due to antigenic drift causing loss of effectiveness and therefore providing little or no protection against novel influenza A subtypes. Next generation vaccines capable of eliciting CD8(+) T cell (CTL) mediated cross-protective immunity may offer a long-term alternative strategy. However, measuring pre- and existing levels of CTL cross-protection in humans is confounded by differences in infection histories across individuals. During 2000-2003, H1N2 viruses circulated persistently in the human population for the first time and we hypothesized that the viral nucleoprotein (NP) contained novel CTL epitopes that may have contributed to the survival of the viruses. This study describes the immunogenic NP peptides of H1N1, H2N2, and H3N2 influenza viruses isolated from humans over the past century, 1918-2003, by comparing this historical dataset to reference NP peptides from H1N2 that circulated in humans during 2000-2003. Observed peptides sequences ranged from highly conserved (15%) to highly variable (12%), with variation unrelated to reported immunodominance. No unique NP peptides which were exclusive to the H1N2 viruses were noted. However, the virus had inherited the NP from a recently emerged H3N2 variant containing novel peptides, which may have assisted its persistence. Any advantage due to this novelty was subsequently lost with emergence of a newer H3N2 variant in 2003. Our approach has potential to provide insight into the population context in which influenza viruses emerge, and may help to inform immunogenic peptide selection for CTL-inducing influenza vaccines. J. Med. Virol. 88:1725-1732, 2016. © 2016 Wiley Periodicals, Inc.
当前的季节性流感疫苗由于抗原漂移导致效力丧失,因此需要定期更新,对新型甲型流感亚群几乎没有或没有保护作用。能够引发 CD8(+)T 细胞 (CTL) 介导的交叉保护免疫的下一代疫苗可能提供一种长期的替代策略。然而,由于个体之间的感染史不同,测量人类 CTL 交叉保护的预先存在的水平是复杂的。在 2000-2003 年期间,H1N2 病毒首次在人群中持续传播,我们假设病毒核蛋白 (NP) 中含有可能有助于病毒存活的新型 CTL 表位。本研究通过将这一历史数据集与 2000-2003 年在人类中传播的 H1N2 参考 NP 肽进行比较,描述了过去一个世纪(1918-2003 年)从人类中分离的 H1N1、H2N2 和 H3N2 流感病毒的免疫原性 NP 肽。观察到的肽序列范围从高度保守(15%)到高度可变(12%),变异与报道的免疫优势无关。未注意到仅存在于 H1N2 病毒中的独特 NP 肽。然而,该病毒从一种最近出现的含有新型肽的 H3N2 变体中继承了 NP,这可能有助于其持续存在。由于这种新颖性的任何优势随后都随着 2003 年出现一种更新的 H3N2 变体而丧失。我们的方法有可能深入了解流感病毒出现的人群背景,并可能有助于为诱导 CTL 的流感疫苗的免疫原性肽选择提供信息。J. Med. Virol. 88:1725-1732, 2016。©2016 Wiley Periodicals, Inc.